Public Engagement and Clinical Trials: New Models and Disruptive Technologies: Workshop Summary | Agenda Bookshop Skip to content
Online orders placed from 19/12 onward will not arrive in time for Christmas.
Online orders placed from 19/12 onward will not arrive in time for Christmas.
A01=and Translation
A01=Board on Health Sciences Policy
A01=Development
A01=Forum on Drug Discovery
A01=Forum on Drug Discovery Development and Translation
A01=Institute of Medicine
Age Group_Uncategorized
Age Group_Uncategorized
and Translation
Author_and Translation
Author_Board on Health Sciences Policy
Author_Development
Author_Forum on Drug Discovery
Author_Forum on Drug Discovery Development and Translation
Author_Institute of Medicine
automatic-update
B01=Anne B. Claiborne
B01=Rebecca A. English
B01=Victoria Weisfeld
Category1=Non-Fiction
Category=MBGR1
Category=MBN
COP=United States
Delivery_Delivery within 10-20 working days
Development
Language_English
PA=Available
Price_€20 to €50
PS=Active
softlaunch

Public Engagement and Clinical Trials: New Models and Disruptive Technologies: Workshop Summary

Clinical trials provide essential information needed to turn basic medical research findings into patient treatments. New treatments must be studied in large numbers of humans to find out whether they are effective and to assess any harm that may arise from treatment. There is growing recognition among many stakeholders that the U.S. clinical trials enterprise is unable to keep pace with the national demand for research results. The IOM, along with the Mount Sinai School of Medicine, held a workshop June 27-28, 2011, to engage stakeholders and experts in a discussion about possible solutions to improve public engagement in clinical trials.

Table of Contents
  • Front Matter
  • 1 Introduction
  • 2 Framing the Problem
  • 3 Recruitment Challenges in Clinical Trials for Different Diseases and Conditions
  • 4 Models for Public Engagement
  • 5 Messages and Methods for Public Engagement
  • 6 The Media
  • 7 Novel Clinical Trial Designs
  • 8 The Health System's Structure and Culture
  • 9 Toward a Patient-Centered Strategy for Clinical Trials
  • References
  • Appendix A: Workshop Agenda
  • Appendix B: The Clinical Trials Process
  • Appendix C: Participant Biographies
See more
Current price €41.79
Original price €43.99
Save 5%
A01=and TranslationA01=Board on Health Sciences PolicyA01=DevelopmentA01=Forum on Drug DiscoveryA01=Forum on Drug Discovery Development and TranslationA01=Institute of MedicineAge Group_Uncategorizedand TranslationAuthor_and TranslationAuthor_Board on Health Sciences PolicyAuthor_DevelopmentAuthor_Forum on Drug DiscoveryAuthor_Forum on Drug Discovery Development and TranslationAuthor_Institute of Medicineautomatic-updateB01=Anne B. ClaiborneB01=Rebecca A. EnglishB01=Victoria WeisfeldCategory1=Non-FictionCategory=MBGR1Category=MBNCOP=United StatesDelivery_Delivery within 10-20 working daysDevelopmentLanguage_EnglishPA=AvailablePrice_€20 to €50PS=Activesoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Dimensions: 152 x 229mm
  • Publication Date: 17 Mar 2012
  • Publisher: National Academies Press
  • Publication City/Country: United States
  • Language: English
  • ISBN13: 9780309219297
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept